Literature DB >> 31049411

GPs' perspectives on colorectal cancer screening and their potential influence on FIT-positive patients: an exploratory qualitative study from a Dutch context.

Lucinda Bertels1, Sientje van der Heijden2, Maartje Hoogsteyns3, Evelien Dekker4, Kristel van Asselt5, Henk van Weert6, Bart Knottnerus5.   

Abstract

BACKGROUND: In the Dutch colorectal cancer (CRC) screening programme, individuals receive a faecal immunochemical test (FIT) to do at home. After a positive FIT result, a follow-up colonoscopy is recommended to identify CRC or advanced adenomas (AA). GPs may influence their patients' decisions on adherence to follow-up by colonoscopy. AIM: To explore GPs' perspectives on the CRC screening programme and their potential influence on FIT-positive patients to follow up with the recommended colonoscopy. DESIGN &
SETTING: Semi-structured interviews among GPs in Amsterdam, the Netherlands.
METHOD: GPs were approached using purposive sampling. Analysis was performed on 11 interviews using open coding and constant comparison.
RESULTS: All interviewed GPs would recommend FIT-positive patients without obvious contraindications to adhere to a follow-up colonoscopy. If patients were likely to be distressed by a positive FIT result, most GPs described using reassurance strategies emphasising a low cancer probability. Most GPs stressed the probability of false-positive FIT results. Some described taking a positive screening result in CRC screening less seriously than one in breast cancer screening. Most GPs underestimated CRC and AA probabilities after a positive FIT result. When told the actual probabilities, some stated that this knowledge might change the way they would inform patients.
CONCLUSION: These results imply that some of the interviewed GPs have too low a perception of the risk associated with a positive FIT result, which might influence their patients' decision-making. Simply informing GPs about the actual rates of CRC and AA found in the screening programme might improve this risk perception.

Entities:  

Keywords:  Colorectal Cancer Screening; Colorectal Neoplasms; Early Detection of Cancer; Family Practice; Primary Health Care; Qualitative Research

Year:  2019        PMID: 31049411      PMCID: PMC6480863          DOI: 10.3399/bjgpopen18X101631

Source DB:  PubMed          Journal:  BJGP Open        ISSN: 2398-3795


  22 in total

1.  Participation in screening for colorectal cancer based on a faecal occult blood test is improved by endorsement by the primary care practitioner.

Authors:  S R Cole; G P Young; D Byrne; J R Guy; J Morcom
Journal:  J Med Screen       Date:  2002       Impact factor: 2.136

2.  Survey on colorectal cancer screening knowledge, attitudes, and practices of general practice physicians in Lazio, Italy.

Authors:  Antonio Federici; Paolo Giorgi Rossi; Francesco Bartolozzi; Sara Farchi; Piero Borgia; Gabriella Guasticchi; Gabriella Guastcchi
Journal:  Prev Med       Date:  2004-12-30       Impact factor: 4.018

3.  The role of GPs in increasing compliance to colorectal cancer screening: a randomised controlled trial (Italy).

Authors:  Antonio Federici; Paolo Giorgi Rossi; Francesco Bartolozzi; Sara Farchi; Piero Borgia; Gabriella Guastcchi
Journal:  Cancer Causes Control       Date:  2006-02       Impact factor: 2.506

4.  Endorsement by the primary care practitioner consistently improves participation in screening for colorectal cancer: a longitudinal analysis.

Authors:  I T Zajac; A H Whibley; S R Cole; D Byrne; J Guy; J Morcom; G P Young
Journal:  J Med Screen       Date:  2010       Impact factor: 2.136

5.  Characteristics of advanced adenomas detected at CT colonographic screening: implications for appropriate polyp size thresholds for polypectomy versus surveillance.

Authors:  David H Kim; Perry J Pickhardt; Andrew J Taylor
Journal:  AJR Am J Roentgenol       Date:  2007-04       Impact factor: 3.959

6.  Obstacles to colorectal screening in general practice: a qualitative study of GPs and patients.

Authors:  Isabelle Aubin-Auger; Alain Mercier; Jean-Pierre Lebeau; Laurence Baumann; Lieve Peremans; Paul Van Royen
Journal:  Fam Pract       Date:  2011-05-06       Impact factor: 2.267

7.  The influence of physicians on colorectal cancer screening behavior.

Authors:  Maria Y Ho; Jennifer Y Lai; Winson Y Cheung
Journal:  Cancer Causes Control       Date:  2011-10-05       Impact factor: 2.506

8.  Primary care utilization and colorectal cancer outcomes among Medicare beneficiaries.

Authors:  Jeanne M Ferrante; Ellen P McCarthy; Eduardo C Gonzalez; Ji-Hyun Lee; Ren Chen; Kymia Love-Jackson; Richard G Roetzheim
Journal:  Arch Intern Med       Date:  2011-10-24

9.  Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation.

Authors:  Masahito Jimbo; Ronald E Myers; Birgit Meyer; Terry Hyslop; James Cocroft; Barbara J Turner; David S Weinberg
Journal:  Ann Fam Med       Date:  2009 Jan-Feb       Impact factor: 5.166

10.  Barriers to and facilitators of colorectal cancer screening in different population subgroups in Adelaide, South Australia.

Authors:  Sara Javanparast; Paul R Ward; Stacy M Carter; Carlene J Wilson
Journal:  Med J Aust       Date:  2012-05-07       Impact factor: 7.738

View more
  2 in total

1.  What can We Learn From High-Performing Screening Programs to Increase Bowel Cancer Screening Participation in Australia?

Authors:  Louisa Flander; Evelien Dekker; Berit Andersen; Mette Bach Larsen; Robert J Steele; Nea Malila; Tytti Sarkeala; Manon van der Vlugt; Clasine de Klerk; Bart Knottnerus; Lucinda Bertels; Anke Woudstra; Manon C W Spaander; Mirjam Fransen; Sirpa Heinavaara; Mary Dillon; Driss Ait Ouakrim; Mark Jenkins
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

2.  Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer.

Authors:  Manuel Zorzi; Jessica Battagello; Kevin Selby; Giulia Capodaglio; Susanna Baracco; Silvia Rizzato; Enrico Chinellato; Stefano Guzzinati; Massimo Rugge
Journal:  Gut       Date:  2021-03-31       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.